4D Pharma

13 articles with 4D Pharma

• 4D pharma plc: Oncology Programmes Update

  7/25/2019

  Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299 Presented

• 4D pharma plc Commences Phase I/II Asthma Trial

  7/8/2019

  4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutics, announces an update on its lead Live Biotherapeutic candidate for asthma, MRx-4DP0004.

• 4D Presents MRx0518 Combination Study at ASCO 2019, Chicago, USA

  6/3/2019

  4D pharma plc announces the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid tumours who have failed prior anti-PD-1 therapy at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago, USA.

• 4D Presents Phase Ib Clinical Data on Thetanix®

  5/16/2019

  4D pharma plc, a pharmaceutical company focusing on the development of Live Biotherapeutics, announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn's disease will be presented on 18 May in a poster session at the 2019 Digestive Disease Week meeting in San Diego.

• 4D Announces Participation in Neuro4D Conference, Frankfurt, Germany

  5/13/2019

  4D pharma plc announces its participation in the Neuro4D conference, Frankfurt, Germany, 13-14 May, 2019.

• 4D Pharma Clinical Update - MRx0518 Oncology Programmes

  4/29/2019

  4D pharma plc announces an update on the clinical progress of its lead oncology Live Biotherapeutic MRx0518.

• 4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518

  1/29/2019

  4D Pharma plc announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518.

• 4D pharma plc: Appointment of Independent Non-Executive Directors

  1/8/2019

  4D pharma plc today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

• MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors

  1/7/2019

  The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.

• 4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours

  1/7/2019

  4D pharma plc and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.

• 4D Presents at IHMC 2018

  6/27/2018

  Dr. Alex Stevenson, has spoken at the International Human Microbiome Consortium (IHMC) 2018 on the importance of function in the development of live biotherapeutics.

• 4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

  6/7/2018

  4D pharma plc is a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products

• Manchester's 4D Pharma Reels In $29 Million

  6/26/2014